Winnipeg, Canada

Howard A Kaplan


Average Co-Inventor Count = 3.0

ph-index = 1

Forward Citations = 75(Granted Patents)


Company Filing History:


Years Active: 2001-2006

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Howard A Kaplan: Innovator in Cancer Detection and Treatment

Introduction

Howard A Kaplan is a prominent inventor based in Winnipeg, Canada. He has made significant contributions to the field of cancer detection and treatment through his innovative research and patented inventions. With a total of 2 patents, Kaplan's work focuses on monoclonal antibodies and their applications in oncology.

Latest Patents

Kaplan's latest patents include groundbreaking inventions related to antigen binding fragments that specifically detect cancer cells. His work involves the monoclonal antibody H11 and its ability to bind to the C-antigen, which is found exclusively on neoplastic cells. This invention not only aids in the diagnosis and localization of cancers but also provides methods for treating various neoplastic diseases, including melanoma, neuroblastoma, glioma, soft tissue sarcoma, and small cell lung carcinoma. The H11 antibody has shown promise in reducing the risk of recurrence in patients who are in remission from traditional cancer therapies.

Career Highlights

Howard A Kaplan is associated with Viventia Biotech Inc., where he continues to advance his research in cancer therapeutics. His innovative approach to developing antibody-based treatments has positioned him as a key figure in the biotechnology sector.

Collaborations

Kaplan has collaborated with notable colleagues, including Michael D Dan and Pradip K Maiti, to further enhance the impact of his research in the field of cancer treatment.

Conclusion

Howard A Kaplan's contributions to cancer detection and treatment through his patented inventions highlight his dedication to improving patient outcomes. His work exemplifies the importance of innovation in the fight against cancer.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…